By conjugating nanoparticles with ligands that selectively bind to proteins overexpressed in specific tumor types, such as HER2 in breast cancers or CD44 in certain bladder cancers, researchers can utilize the enhanced imaging capabilities of these systems to delineate subtype features with improved clarity [122]. The gene discussed is ERBB2; the disease is breast carcinoma.